Aprotinin is a serine protease inhibitor used to reduce the risk for perioperative blood loss and the need for blood transfusion in high-risk patients during cardiopulmonary bypass for coronary artery bypass graft surgery. Aprotinin is a protein-based drug that is also known as bovine pancreatic trypsin inhibitor (BPTI).
- Mechanism
- Curator reviewed
Aprotinin inhibits serine proteases including trypsin, chymotrypsin and plasmin at a concentration of about 125,000 IU/mL, and kallikrein at 300,000 IU/mL. The inhibition of kallikrein inhibits formation of factor XIIa. This inhibits the intrinsic pathway of coagulation and fibrinolysis. Inhibition of plasmin also slows fibrinolysis.
- Primary indication
- For prophylactic use to reduce perioperative blood loss and the need for blood transfusion in patients undergoing cardiopulmonary bypass in the course of coronary artery bypass graft surgery who are at an increased risk for...Curator reviewed · 3 structured indications
- Formula / weight
- C284H432N84O79S7 · 6511.439 Da
- First approval
- Canada, 2014 · United States, 1993
- Also known as
- Aprotinin (bovine) · Aprotinin biosynthetic · Aprotinin bovine · Aprotinin concentrated solution · Bovine aprotinin
- Code names
- 232-994-9 · BAYERA-128 · Riker-52G · RP-9921
- Brand names
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Aprotinin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account